Pharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis

Koch, 1993, Pathogenesis of cystic fibrosis, Lancet, 341, 1065, 10.1016/0140-6736(93)92422-P Fitzsimmons, 1993, The changing epidemiology of cystic fibrosis, J Pediatr, 122, 1, 10.1016/S0022-3476(05)83478-X Konstan, 1993, Infection and inflammation of the lung in cystic fibrosis, vol 64, 219 Turpin, 1993, Treatment of pulmonary disease in patients with cystic fibrosis, 277 Mendelman, 1985, Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum, Am Rev Respir Dis, 132, 761 Klastersky, 1981, Comparative studies of intermittent and continuous administration of aminoglycosides in the treatment of bronchopulmonary infections due to gram-negative bacteria, Rev Infect Dis, 3, 74, 10.1093/clinids/3.1.74 Alexander, 1982, Bronchial secretion concentrations of tobramycin, Am Rev Respir Dis, 125, 208 Braude, 1983, Pulmonary disposition of tobramycin, Am Rev Respir Dis, 127, 563, 10.1164/arrd.1983.127.5.563 McCrae, 1976, Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum, J Infect Dis, 134, S191, 10.1093/infdis/134.Supplement_1.S191 Levy, 1983, Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum, J Infect Dis, 148, 1069, 10.1093/infdis/148.6.1069 American Academy of Otolaryngology, 1979, Guide for the evaluation of hearing handicap, JAMA, 241, 2055, 10.1001/jama.1979.03290450053025 Brummett, 1980, Drug-induced ototoxicity, Drugs, 19, 412, 10.2165/00003495-198019060-00002 MacLusky, 1986, Inhaled antibiotics in cystic fibrosis: is there a therapeutic effect?, J Pediatr, 108, 861, 10.1016/S0022-3476(86)80758-2 Touw, 1995, Inhalation of antibiotics in cystic fibrosis, Eur Respir J, 8, 1594 Rosenfeld, 1997, Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy, and pitfalls, Clin Pulm Med, 4, 101, 10.1097/00045413-199703000-00006 Weber, 1994, Nebulizer delivery of tobramycin to the lower respiratory tract, Pediatr Pulmonol, 17, 331, 10.1002/ppul.1950170511 Eisenberg, 1997, A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems, Chest, 111, 955, 10.1378/chest.111.4.955 Smith, 1989, Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis, Pediatr Pulmonol, 7, 265, 10.1002/ppul.1950070413 Wall, 1983, Inhaled antibiotics in cystic fibrosis [letter], Lancet, 1, 1325, 10.1016/S0140-6736(83)92428-5 Carswell, 1987, A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis, Br J Dis Chest, 81, 356, 10.1016/0007-0971(87)90184-7 Steinkamp, 1989, Long-term tobramycin aerosol therapy in cystic fibrosis, Pediatr Pulmonol, 6, 91, 10.1002/ppul.1950060207 MacLusky, 1989, Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa, Pediatr Pulmonol, 7, 42, 10.1002/ppul.1950070110 Ramsey, 1993, Efficacy of aerosolized tobramycin in patients with cystic fibrosis, N Engl J Med, 328, 1740, 10.1056/NEJM199306173282403 Stephens, 1983, Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis, Pediatr Infect Dis J, 2, 209, 10.1097/00006454-198305000-00007 Mukhopadhyay, 1993, Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis, J Antimicrob Chemother, 31, 429, 10.1093/jac/31.3.429 Weber, 1995, Tobramycin serum concentrations after aerosol and oral administration in cystic fibrosis, Am J Ther, 2, 81, 10.1097/00045391-199502000-00002 Touw, 1997, Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis, Antimicrob Agents Chemother, 41, 184, 10.1128/AAC.41.1.184 Ramsey, 1998, Interim analysis of data from an open-label follow-on trial of inhaled tobramycin (PC-TNDS-004) in patients with cystic fibrosis [abstract], Pediatr Pulmonol, 17, 320 Ramsey, 1999, Intermittent administration of inhaled tobramycin in patients with cystic fibrosis, N Engl J Med, 340, 23, 10.1056/NEJM199901073400104 Nikolaizik, 1996, Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis, Eur J Pediatr, 155, 608, 10.1007/BF01957914 Coates, 1998, A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers, Chest, 113, 951, 10.1378/chest.113.4.951 Burns, 1998, Microbiology of sputum from patients at cystic fibrosis centers in the United States, Clin Infect Dis, 27, 158, 10.1086/514631 Barends, 1981, Micro-determination of tobramycin in serum by high-performance liquid chromatography with ultraviolet detection, J Chromatogr, 225, 417, 10.1016/S0378-4347(00)80289-3 Beal, 1992 Gardner, 1988, Standardization of spirometry: a summary of recommendations from the American Thoracic Society (the 1987 update), Ann Intern Med, 108, 217, 10.7326/0003-4819-108-2-217 Knudson, 1983, Changes in the normal maximal expiratory flow-volume curve with growth and aging, Am Rev Respir Dis, 127, 725 Cooney, 1994, Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis, J Clin Pharmacol, 34, 255, 10.1002/j.1552-4604.1994.tb03995.x Levy, 1984, Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study, J Pediatr, 105, 117, 10.1016/S0022-3476(84)80375-3 Town, 1996, Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis, Ther Drug Monit, 18, 562, 10.1097/00007691-199610000-00007 Ilowite, 1987, Quantitative deposition of aerosolized gentamicin in cystic fibrosis, Am Rev Respir Dis, 136, 1445, 10.1164/ajrccm/136.6.1445 Cipolla, 1994, Assessment of aerosol delivery systems for recombinant human deoxyribonuclease, S T P Pharma Sci, 4, 50 Coates, 2001, Effect of size and disease on estimated deposition of drugs administered using jet nebulization in children with cystic fibrosis, Chest, 119, 1123, 10.1378/chest.119.4.1123 Rosenfeld, 2001, Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis, J Pediatr, 139, 572, 10.1067/mpd.2001.117785 Diot, 1997, RhDNase I aerosol deposition and related factors in cystic fibrosis, Am J Respir Crit Care Med, 156, 1662, 10.1164/ajrccm.156.5.9604093